Skip to content

ARTHR-IS (Arthroplasties' Infections Due to Staphylococcus Aureus)

Retrospective Study to Identify the Incidence, Risk Factors and Outcomes of Prosthetic Joint Infection Due to Staphylococcus Aureus After Primary Knee or Hip Joint Replacement

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03826108
Enrollment
600
Registered
2019-02-01
Start date
2019-04-16
Completion date
2020-12-31
Last updated
2019-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty Complications, Prosthetic Joint Infection, Staphylococcus Aureus

Brief summary

The number of arthroplasties is expected to grow in the next few years. Staphylococcus aureus (SA) is a primary cause of prosthetic joint infection (PJI) with serious consequences. This microorganism is frequently associated with treatment failure, hospitalizations and need of prosthesis removal, leading to an important morbidity and an increase in healthcare costs. ARTHR-IS is a retrospective multi-center study which aims to estimate the burden of SA-PJI after a hip or knee arthroplasty and their risk factors. Other objectives are to quantify the costs, the number of hospitalizations and the surgical procedures needed to treat and control the infection and finally the factors influencing therapeutic failure. Through a case-control design, ARTHR-IS will group 20 hospitals across 5 European countries in order to include 150 cases and 450 controls. The results of this study will provide critical information to develop strategies to prevent and treat SA-PJI and reduce treatment failures. Also, the results from ARTH-IS study will help in the design of future clinical trials in prosthesis infections by providing reliable estimates on the incidence of SA-PJI and the subsequent burden on health care services.

Interventions

None listed

Sponsors

GlaxoSmithKline
CollaboratorINDUSTRY
Hospital Universitario Virgen Macarena
CollaboratorOTHER
UMC Utrecht
CollaboratorOTHER
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who underwent a primary hip or knee arthroplasty between 2013 and 2016. * Diagnosis of SA -PJI in the first 12 months after primary arthroplasty.

Exclusion criteria

• Patients with a previous SA infection or prosthesis revision on the index joint (joint which was replaced during arthroplasty).

Design outcomes

Primary

MeasureTime frameDescription
Occurrence of the first SA-PJI after a primary joint arthroplasty1 year
Occurrence of medical events after SA-PJI18 monthsEvents to be traced after the SA-PJI infection are: * Hospital readmission * Total hospitalization days * Joint surgical procedures (debridement, removal and replacement of joint prosthesis) * All cause and SA-PJI related mortality

Secondary

MeasureTime frameDescription
Clinical or microbiological failure after the SA-PJI18 monthsClinical failure will be considered to be present if the patient died due to complications related to SA-PJI or if any of the following will be present by the end of the 18 months follow up period after the diagnosis of the first SA-PJI: joint pain or swelling causing an impaired functionality; persistent sinus tract; need for antibiotic treatment for PJI, arthrodesis or amputation. Microbiological failure is defined as any isolation of SA from the joint, periarticular tissues or the blood that was not resolved by the end of the 18th month after the diagnosis of the first SA-PJI.

Countries

Spain

Contacts

Primary ContactReinaldo Espindola, MD
reinaldoespindola@outlook.com0034650107427
Backup ContactMaria Dolores del Toro, MD
mdeltoro@us.es0034653937488

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026